VPS54L: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

Target Name: VPS54

NCBI ID: G51542

VPS54

VPS54L: A Potential Drug Target and Biomarker for Neurodegenerative Diseases

VPS54 (VPS54L) is a protein that is expressed in various tissues and organs, including the brain, heart, liver, and kidneys. It is a member of the voltage-dependent potassium channels (VDJ) family and is involved in the regulation of ion channels and electrical activities in these tissues.

The VPS54 gene was identified as a potential drug target in the field of neurodegenerative diseases, due to its involvement in the regulation of neurotransmitter release and the maintenance of neuronal excitability. Studies have shown that VPS54L is highly expressed in the brains of individuals with Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Additionally, VPS54L has been shown to play a role in the regulation of neurotransmitter release in models of neuroinflammation, which may contribute to the development of these disorders.

In addition to its potential role in neurodegenerative diseases, VPS54L has also been shown to have potential as a biomarker for these conditions. Studies have shown that VPS54L levels are significantly decreased in the brains of individuals with Alzheimer's disease and Parkinson's disease, and that these levels are also decreased in the brain regions affected by neurodegenerative disorders. Additionally, VPS54L has been shown to be a reliable biomarker for measuring the efficacy of neurodegenerative disease therapies, such as antipsychotic drugs, in animal models of these conditions.

Given the potential implications of VPS54L as a drug target and biomarker, there is significant interest in studying its underlying mechanisms and developing new treatments based on its properties. Researchers are currently working to understand how VPS54L functions in the regulation of ion channels and electrical activities in various tissues, as well as how it contributes to the development and progression of neurodegenerative diseases.

In addition to its potential as a drug target and biomarker, VPS54L also has important clinical implications in the treatment of neurodegenerative diseases. Given the high expression of VPS54L in various tissues and the evidence of its involvement in the regulation of neurotransmitter release, researchers are exploring the potential of using VPS54L as a target for new therapies for neurodegenerative diseases.

One approach being explored is the use of small molecules to modulate VPS54L function and improve the efficacy of neurodegenerative disease treatments. Researchers are also investigating the use of VPS54L as a biomarker to monitor the effectiveness of these therapies and to identify potential drug targets for neurodegenerative diseases.

Overall, VPS54L is a protein that has significant potential as a drug target and biomarker for neurodegenerative diseases. Its involvement in the regulation of ion channels and electrical activities in various tissues makes it an attractive target for new therapies, and its high expression in the brains of individuals with neurodegenerative disorders makes it an important biomarker for these conditions. Further research is needed to fully understand the mechanisms of VPS54L's function in neurodegenerative diseases and to develop new treatments based on its properties.

Protein Name: VPS54 Subunit Of GARP Complex

Functions: Acts as component of the GARP complex that is involved in retrograde transport from early and late endosomes to the trans-Golgi network (TGN). The GARP complex is required for the maintenance of the cycling of mannose 6-phosphate receptors between the TGN and endosomes, this cycling is necessary for proper lysosomal sorting of acid hydrolases such as CTSD (PubMed:18367545). Within the GARP complex, required to tether the complex to the TGN. Not involved in endocytic recycling (PubMed:25799061)

The "VPS54 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VPS54 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets